Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes.

Autor: Tyan K; Harvard Medical School, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Bae JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lorch JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Margalit DN; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Tishler RB; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Huynh MA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA., Jo VY; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA., Haddad RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chau NG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; BC Cancer, Vancouver Center, Vancouver, British Columbia, Canada., Hanna GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Schoenfeld JD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2022 Mar; Vol. 44 (3), pp. 722-734. Date of Electronic Publication: 2021 Dec 19.
DOI: 10.1002/hed.26964
Abstrakt: Background: There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC).
Methods: Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1-5 lesions) at any point during follow-up.
Results: There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14-0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02-0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07-0.71).
Conclusions: There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: